Last updated: September 4, 2026
Ivosidenib, marketed as Tibsovo by Servier, is a targeted inhibitor of mutant IDH1 used in acute myeloid leukemia (AML) and previously treated IDH1-mutated cholangiocarcinoma. Its commercial position is supported by biomarker-defined prescribing, orphan-drug protection, a differentiated mechanism, and a core composition-of-matter patent family extending into the early 2030s. The main constraints are the small IDH1-positive population, competition from other targeted AML therapies, limited label breadth, and the absence of publicly disclosed product-level revenue.
Through June 2024, Tibsovo remained a protected specialty-oncology product with no established generic or biosimilar substitute. Its highest-value commercial opportunity is AML, particularly older patients and patients unable to receive intensive induction therapy. Cholangiocarcinoma provides a smaller indication with a narrower treatment population.
What is ivosidenib and which markets does Tibsovo address?
Ivosidenib is an oral, once-daily small-molecule inhibitor of mutant isocitrate dehydrogenase 1, or IDH1. The drug inhibits the abnormal enzyme activity associated with IDH1 mutations and reduces production of the oncometabolite 2-hydroxyglutarate.
Servier acquired global rights to ivosidenib from Agios Pharmaceuticals in 2020. Agios retained rights to certain economics in the United States under the transaction structure, while Servier assumed commercial responsibility for Tibsovo.[1]
| Product |
Active ingredient |
Company |
Main indications |
| Tibsovo |
Ivosidenib |
Servier |
IDH1-mutated AML; previously treated IDH1-mutated cholangiocarcinoma |
| Development code |
AG-120 |
Agios, later Servier |
Targeted IDH1 inhibition |
The commercial market is defined by molecular testing rather than by the full AML or cholangiocarcinoma population. Patients must have a susceptible IDH1 mutation, generally identified through an FDA-cleared diagnostic assay or validated testing method.
What FDA approvals does ivosidenib have?
Ivosidenib has three major U.S. AML label milestones and one cholangiocarcinoma approval.
| FDA milestone |
Date |
Commercial significance |
| Relapsed or refractory AML with a susceptible IDH1 mutation |
July 20, 2018 |
First U.S. approval; established ivosidenib as an IDH1-directed AML therapy |
| Previously treated, locally advanced or metastatic cholangiocarcinoma with a susceptible IDH1 mutation |
August 25, 2021 |
Added a solid-tumor indication |
| Newly diagnosed AML in patients age 75 or older, or with comorbidities precluding intensive induction chemotherapy |
May 25, 2022 |
Expanded use into frontline lower-intensity treatment |
| Current regulatory status through June 2024 |
Approved |
No FDA biosimilar pathway applies because ivosidenib is a small molecule |
The AML approvals are based on different clinical-use settings. The original approval addressed relapsed or refractory disease. The 2022 expansion targeted newly diagnosed patients who are often older, medically frail, or unsuitable for intensive chemotherapy. That expansion increased the addressable market but placed Tibsovo against venetoclax-based low-intensity regimens and other targeted approaches.[2]
The cholangiocarcinoma approval was based on the ClarIDHy study, which showed a progression-free-survival benefit in previously treated IDH1-mutated disease. The label is restricted to patients with a susceptible IDH1 mutation and prior treatment.[3]
When does ivosidenib lose exclusivity?
Ivosidenib’s practical loss-of-exclusivity date is likely driven by patent expiration rather than FDA regulatory exclusivity.
| Protection type |
Estimated or statutory period |
Commercial effect |
| New chemical entity exclusivity |
Five years from the 2018 approval |
Expired in 2023 |
| AML orphan-drug exclusivity |
Seven years from the relevant approval |
Initial AML protection reached the mid-2020s |
| Cholangiocarcinoma orphan-drug exclusivity |
Seven years from the 2021 approval |
Potentially extends into 2028 for the protected indication |
| Core composition patent family |
Approximately through 2033 before any applicable adjustment |
Primary barrier to broad generic substitution |
| Pediatric exclusivity |
No material public basis for assuming a six-month extension |
Should not be included in the base-case loss-of-exclusivity model |
The 2018 approval’s five-year new chemical entity period ended in 2023. NCE protection prevented an ANDA applicant from relying on the full FDA approval for five years, but it did not independently prevent all forms of competing development after that date.
Orphan-drug exclusivity is indication-specific. It does not create a universal seven-year monopoly over every use of ivosidenib. A competitor may face different restrictions depending on whether it seeks approval for the same orphan indication, a different indication, or a non-overlapping use.
The core patent estate is expected to remain the principal U.S. barrier after regulatory exclusivity ends. Public patent records identify U.S. Patent No. 9,266,857 as part of the foundational IDH1-inhibitor family associated with ivosidenib. Its nominal term extends into 2033, subject to patent-term adjustment and any relevant terminal-disclaimer or prosecution details.[4]
What patents protect ivosidenib?
The patent estate includes composition, pharmaceutical-composition, treatment-method, and potentially solid-state or manufacturing claims. The most commercially important claims are those covering the active compound and its use in IDH1-mutated cancers.
Representative protection categories
| Patent category |
Scope |
Generic risk |
| Composition of matter |
Ivosidenib molecule and related chemical embodiments |
Highest barrier to direct generic substitution |
| Pharmaceutical composition |
Tablets, excipients, and dosage forms |
Can restrict formulation copying |
| Method of use |
Treating IDH1-mutated AML and other cancers |
Supports indication-specific enforcement |
| Biomarker-directed treatment |
Selecting patients with susceptible IDH1 mutations |
Important for label and induced-infringement analysis |
| Manufacturing and process claims |
Synthesis, intermediates, or purification |
Can complicate supply-chain replication |
The patent estate is stronger when a composition patent remains enforceable because an ANDA applicant cannot avoid infringement merely by using a different manufacturing process. Method-of-use patents are narrower. They can be carved out through a section viii statement or a label that omits the patented indication, although real-world prescribing and promotional conduct can create separate litigation issues.
The Orange Book status should be evaluated patent-by-patent because FDA listings can change through patent expiry, delisting, corrections, or litigation outcomes. The core commercial question is whether the listed composition claims remain enforceable through the early 2030s, not whether every method-of-use patent survives that long.
Which companies are challenging ivosidenib?
Through June 2024, no material public generic launch had displaced Tibsovo, and no established biosimilar challenge was relevant. Biosimilars do not apply to ivosidenib because it is a chemically synthesized small molecule, not a biologic.
The principal competitive threats were therapeutic rather than generic.
| Competitor or therapy |
Company |
Overlap with Tibsovo |
| Enasidenib |
Servier |
IDH2 inhibitor for AML; complementary rather than direct IDH1 competition |
| Olutasidenib |
Rigel Pharmaceuticals |
Direct IDH1-mutated relapsed or refractory AML competitor |
| Azacitidine plus venetoclax |
Various |
Major frontline lower-intensity AML regimen competing with single-agent or combination targeted therapy |
| Intensive chemotherapy |
Multiple providers |
Competes in fit, newly diagnosed patients |
| Clinical-trial combinations |
Multiple developers |
Potential future competition in IDH1-mutated AML |
Olutasidenib is the most direct approved small-molecule competitor in IDH1-mutated AML. Its positioning in relapsed or refractory disease increases payer and physician choice, although the two drugs differ in clinical data, dosing, safety, and label details.[5]
Venetoclax-based regimens exert broader commercial pressure because they address a much larger AML population. Ivosidenib’s strongest positioning is in patients with a confirmed IDH1 mutation and in treatment settings where an oral, mutation-directed option is clinically attractive.
What generic entry risks exist for Tibsovo?
The base-case generic entry risk is low before the core composition patent family expires. The principal risk is an ANDA filing with a Paragraph IV certification alleging that listed patents are invalid, unenforceable, or not infringed.
A Paragraph IV filing could create three possible outcomes:
- Servier or another patent owner files suit within 45 days, triggering a statutory 30-month stay of ANDA approval unless the litigation is resolved earlier.
- The generic applicant launches at risk after an adverse court decision or after the stay expires.
- The parties settle, potentially with a licensed entry date before patent expiry.
No publicly disclosed settlement establishing an early generic launch date was identified through June 2024. The absence of a public settlement does not establish that no ANDA activity exists, because regulatory submissions and confidential commercial negotiations may precede litigation disclosure.
Potential generic entry scenarios are:
| Scenario |
Likely timing |
Market effect |
| No successful Paragraph IV challenge |
After core patent expiry, likely early-to-mid 2030s |
Gradual substitution and price erosion |
| Successful invalidity or non-infringement challenge |
Before patent expiry |
Rapid price decline in the affected indication |
| Carve-out launch |
Earlier than full-label entry |
Limited share capture in non-patented uses |
| Authorized generic or license |
Contract-dependent |
Controlled erosion with retained economics for the originator |
How strong is the ivosidenib patent estate?
The estate is commercially meaningful but not uniformly strong across all claim types.
Composition claims provide the best protection because they cover the active molecule regardless of indication. Method-of-use claims are more vulnerable to design-around strategies, label carve-outs, and disputes over induced infringement. Formulation claims can protect the marketed tablet but are less valuable if a generic can develop a non-infringing formulation.
The estate’s strength is supported by:
- A long-lived core composition family.
- Multiple approved uses in AML and cholangiocarcinoma.
- Biomarker-based treatment claims linked to a defined patient population.
- The difficulty of substituting another IDH1 inhibitor without generating new clinical and regulatory evidence.
Its weaknesses include:
- A relatively small biomarker-defined population.
- Competition from another approved IDH1 inhibitor in AML.
- The ability of generic applicants to attack individual patents rather than the entire commercial program.
- Limited protection from biologic-style manufacturing barriers because ivosidenib is a small molecule.
What is the financial trajectory for Tibsovo?
Servier does not publicly report a standalone Tibsovo revenue line in the manner of a listed pharmaceutical company with product-level quarterly reporting. A precise product revenue series, operating margin, and free-cash-flow contribution therefore cannot be independently confirmed from Servier’s public financial disclosures.
The commercial trajectory has likely followed four stages:
| Period |
Business phase |
Financial implication |
| 2018-2020 |
AML launch and market formation |
Initial specialty-oncology revenue; limited label breadth |
| 2021 |
Cholangiocarcinoma approval |
Added a second indication and a new orphan-protected revenue stream |
| 2022-2023 |
Frontline AML expansion |
Increased addressable population, especially older and medically unfit patients |
| 2024 onward |
Maturation and competition |
Growth depends on diagnosis rates, treatment duration, combinations, and payer access |
Revenue drivers include mutation testing, adoption in newly diagnosed AML, duration of therapy, use after prior treatment, and international reimbursement. Cholangiocarcinoma is strategically valuable but unlikely to match AML in absolute patient volume.
The economics are typical of a targeted oncology medicine: high gross margin, specialized prescribing, relatively limited unit volume, and substantial dependence on treatment guidelines and diagnostic confirmation. Revenue concentration in AML creates exposure to competing regimens and clinical-trial readouts.
How does ivosidenib compare with other targeted AML drugs?
| Factor |
Ivosidenib |
Olutasidenib |
Enasidenib |
| Molecular target |
Mutant IDH1 |
Mutant IDH1 |
Mutant IDH2 |
| Primary overlap |
IDH1-mutated AML |
IDH1-mutated AML |
IDH2-mutated AML |
| Solid-tumor use |
Cholangiocarcinoma |
No comparable approved solid-tumor indication |
None comparable |
| Commercial differentiation |
AML plus cholangiocarcinoma; earlier-line expansion |
Direct IDH1 AML competition |
Different biomarker population |
| Key market dependency |
IDH1 testing and AML treatment adoption |
IDH1 testing and relapse treatment |
IDH2 testing |
Ivosidenib has a broader approved disease footprint than olutasidenib because of the cholangiocarcinoma label and the 2022 newly diagnosed AML expansion. Its competitive position is less secure in relapsed or refractory AML, where physicians may select between two IDH1-directed options.
What licensing deals affect ivosidenib?
Agios and Servier entered a 2020 transaction under which Servier acquired rights and assumed responsibility for ivosidenib commercialization. The deal included an upfront payment, potential milestone economics, and continuing economics for Agios.[1]
The transaction moved ivosidenib from a development-stage Agios asset into Servier’s broader oncology portfolio. It also gave Servier control over global launch execution, regulatory expansion, and lifecycle management. No separate major licensing agreement was required to create the current U.S. commercial position.
What are the geographic and manufacturing barriers?
Ivosidenib has the highest commercial value in the United States, where AML treatment is concentrated in specialist centers and molecular testing is relatively established. Europe and other markets add revenue but depend on country-specific reimbursement and local regulatory decisions.
Manufacturing is less of a barrier than patent protection. Ivosidenib is a small molecule and does not require the complex cell-culture, cold-chain, or comparability package associated with biologics. A generic manufacturer could potentially reproduce the active ingredient after patent barriers fall, subject to chemistry, manufacturing, and controls requirements.
Key Takeaways
- Ivosidenib is a Servier-targeted oncology product with approved uses in IDH1-mutated AML and previously treated cholangiocarcinoma.
- AML is the main commercial market; the 2022 frontline expansion increased the addressable population.
- The five-year NCE period expired in 2023, but core composition patent protection is expected to extend into the early 2030s.
- Orphan exclusivity is indication-specific and does not create a universal monopoly over all ivosidenib uses.
- Olutasidenib is the main direct IDH1 competitor; venetoclax-based regimens create broader AML pressure.
- No biosimilar pathway applies, and no material public generic launch or early-entry settlement was established through June 2024.
- Servier does not disclose standalone Tibsovo revenue, so product-level financial projections require external prescription, claims, or IQVIA data.
- The strongest IP is the composition-of-matter estate. Method-of-use and formulation claims are more vulnerable to carve-outs and design-around strategies.
FAQs
Is Tibsovo a biologic drug?
No. Tibsovo contains ivosidenib, a chemically synthesized small-molecule drug. It is subject to the conventional generic-drug pathway rather than the FDA biosimilar pathway.
Does ivosidenib have orphan-drug status?
Yes. Ivosidenib received orphan-drug designations for relevant AML and cholangiocarcinoma populations. Orphan exclusivity is tied to the approved indication and does not automatically block all competing uses.
What is the main clinical competitor to Tibsovo?
Olutasidenib is the closest direct competitor because it also targets mutant IDH1 in AML. Venetoclax plus azacitidine is a broader treatment competitor in newly diagnosed AML.
Can a generic manufacturer launch ivosidenib before 2033?
Only through a successful patent challenge, a non-infringing label carve-out, a license or settlement, or another regulatory pathway that avoids enforceable patent claims. A routine full-label generic launch before expiration would face substantial IP risk.
Does Servier report Tibsovo sales separately?
Servier’s public reporting does not generally provide a standalone Tibsovo revenue line. Product-level financial analysis therefore depends on external commercial datasets or company disclosures that separate the product from the broader oncology portfolio.
References
- Agios Pharmaceuticals, Inc. (2020). Agios and Servier enter into definitive agreement for Servier to acquire rights to TIBSOVO in the United States. https://investor.agios.com
- U.S. Food and Drug Administration. (2022). FDA approves ivosidenib for newly diagnosed acute myeloid leukemia. https://www.fda.gov
- U.S. Food and Drug Administration. (2021). FDA approves ivosidenib for advanced or metastatic cholangiocarcinoma. https://www.fda.gov
- United States Patent and Trademark Office. (2016). U.S. Patent No. 9,266,857, inhibitors of mutant IDH1. https://patents.google.com
- U.S. Food and Drug Administration. (2022). FDA approves olutasidenib for relapsed or refractory acute myeloid leukemia. https://www.fda.gov
